SOX Chemotherapy
Sponsors
Ruijin Hospital, The First Affiliated Hospital with Nanjing Medical University, Akeso, West China Hospital, Liaoning Cancer Hospital & Institute
Conditions
AdebrelimabAdenocarcinoma of GE JunctionAdenocarcinoma of StomachAdjuvant TreatmentAdvanced Gastric CancerChemotherapyChemotherapy EffectGC/GEJC
Phase 1
Phase 2
Dragon III: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer
CompletedNCT03636893
Start: 2018-08-24End: 2025-05-08Updated: 2025-07-23
A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer
RecruitingNCT07263386
Start: 2025-10-23End: 2030-10-31Target: 460Updated: 2025-12-04
Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
RecruitingNCT07315854
Start: 2025-11-04End: 2029-12-31Target: 32Updated: 2026-01-06
QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer
Not yet recruitingNCT07315035
Start: 2026-01-01End: 2030-12-31Target: 74Updated: 2026-01-02
Adebrelimab, Apatinib & SOX for Conversion Therapy in Advanced Gastric/GEJ Cancer
RecruitingNCT07353684
Start: 2025-05-11End: 2028-01-31Target: 49Updated: 2026-01-20
Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial
RecruitingNCT07474324
Start: 2026-03-15End: 2030-12-31Target: 124Updated: 2026-03-16
Dynamic ctDNA-Guided Adjuvant Therapy in cStage III and IVA Gastric or Gastroesophageal Junction Adenocarcinoma
Not yet recruitingNCT07507916
Start: 2026-04-01End: 2029-12-31Target: 32Updated: 2026-04-02
Phase 3
Using ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer
Active, not recruitingNCT06939439
Start: 2024-12-01End: 2029-12-31Target: 416Updated: 2025-07-01
A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
RecruitingNCT07023315
Start: 2025-08-14End: 2031-07-01Target: 760Updated: 2026-02-11
Phase 4
Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as an Adjuvant Treatment After Radical Surgery for Patients With Resectable Adenocarcinoma of the Esophagogastric Junction of Gastric Cancer
Not yet recruitingNCT07132528
Start: 2025-08-31End: 2028-09-30Target: 1000Updated: 2025-08-20
Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regimens in Patients With Resectable Gastric Cancer/Adenocarcinoma of the Esophagogastric Junction After Radical Surgery
Not yet recruitingNCT07149181
Start: 2025-08-31End: 2028-09-30Target: 1000Updated: 2025-08-29
Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Adenocarcinoma of the Esophagogastric Junction Who Underwent Radical Surgery After Neoadjuvant Chemotherapy Combined With Immunotherapy and Achieved pCR in Postoperative Pathology
Not yet recruitingNCT07161453
Start: 2025-09-30End: 2027-12-31Target: 500Updated: 2025-09-08